

Press release

Vetter is a winner of the AbbVie TRIUMPH AWARD

Leading CDMO claims prestigious customer award from one of the top-20 biopharmaceutical companies

Ravensburg, Germany, May 11, 2016 – AbbVie, one of the world’s leading biopharmaceutical companies has awarded Vetter, a leading contract manufacturing and development organization (CDMO), the TRIUMPH AWARD for 2015. The award was granted for meeting AbbVie’s ‘predetermined high-level demands of service’. Vetter received this prestigious award as a contract manufacturer in the category *Third-Party Manufacturers - Supplier of the Year*. Recently, Vetter announced that the company won two other coveted awards, the *WorldStar Award 2016* for its syringe closure system Vetter-Ject[®], and the *2016 CMO Leadership Award* in four categories including, quality, capabilities, expertise, and compatibility.

The *AbbVie TRIUMPH AWARD* was created to acknowledge contract service companies whose efforts are ‘well-aligned with the company’s business strategy, and make an important contribution to AbbVie’s strategic vision on a long-term basis’. With this award, granted within a field of more than one thousand contractors, the company recognizes its top performing contract suppliers for efforts that consistently add measureable value, and regularly exceed best-in-class performance on behalf of AbbVie and patients who come to rely on their products. Vetter received this prestigious award as a contract manufacturer for 2015 in the category *Third-Party Manufacturers - Supplier of the Year*. This recognition was achieved by meeting the predetermined high-level demands of service AbbVie has come to expect that is ‘consistently above-average’.

“The winning of this award is especially significant for Vetter as it recognizes our continuing efforts to provide our customers a high-level of service, and it is particularly gratifying since it is from one of the world’s leading biopharmaceutical companies,” said Vetter Managing Director Peter Soelkner. “This award is a reflection of the value that Vetter brings to the biopharmaceutical industry, and consequently to patients worldwide, and is yet another affirmation that Vetter continues to exceed the expectations of our peers in areas of critical importance to their business.” In a speech honoring Vetter for the award, AbbVie highlighted the importance of the good partnership it has forged with Vetter, specifically noting the achievement of a high number of commercial batches, as well as the many project activities performed on the company’s behalf.



Troy Carpenter (President Vetter Pharma International USA - third from right), Casie Thomas (US Key Account Manager), Martin Schwab (Customer Project Manager - second from left) and Alexander Osswald (Team Leader Central Planning - first from left) accepted the Award in a ceremony in April 2016 representing the Vetter project team. They are joined by AbbVie's Terry Simmons (Vice President of Procurement - second from right), and Jose Sevilla (Program Director - first from right).



About Vetter

Vetter is a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with production facilities in Germany and the United States, the contract development and manufacturing organization (CDMO) is an innovative solution provider serving the top 10 (bio-)pharmaceutical companies, as well as small and midsize companies. Its portfolio spans state-of-the-art manufacturing from early clinical development through commercial filling and final packaging of parenteral drugs. The company's extensive experience covers a broad range of complex compounds including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company of approximately 3,600 employees offers a foundation of experience spanning more than 35 years, including dozens of customer product approvals for novel (bio-)pharmaceutical compounds. The CDMO is also committed to patient safety and compliance with user friendly solutions such as Vetter-Ject[®], as well as its dual-chamber syringe Vetter Lyo-Ject[®] and cartridge system V-LK[®]. Vetter's branch office in Singapore and its subsidiary in Tokyo, Japan, increase the presence of the company and the awareness of its service portfolio in the Asian healthcare market. Visit www.vetter-pharma.com.

Contact

Vetter Pharma International GmbH
Oskar Gold
Senior Vice President Key Account Management,
Marketing / Corporate Communications
Eywiesenstrasse 5
88212 Ravensburg
Phone: +49 (0)751-3700-3729
E-mail: PRnews@vetter-pharma.com